Anti-CD3 anti-HER2 activated T cells - Genentech

Drug Profile

Anti-CD3 anti-HER2 activated T cells - Genentech

Alternative Names: Anti-HER2-anti-CD3 activated T cells; HER2-TDB; HER2/CD3; Trastuzumab-based HER2 T cell dependent bispecific antibody

Latest Information Update: 03 Jun 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Apoptosis stimulants; CD3 antigen modulators; Cytotoxic T lymphocyte stimulants; ERBB 2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 09 Apr 2016 Preclinical trials in Breast cancer in USA (Parenteral)
  • 09 Apr 2016 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top